NeurAxis achieves milestone with new Category I CPT code for PENFS therapy.
ByAinvest
Thursday, Jan 8, 2026 8:12 am ET1min read
NRXS--
NeurAxis, a medical technology company, has announced that the Category I CPT code for Percutaneous Electrical Nerve Field Stimulation (PENFS) is now in effect, paving the way for widespread adoption of its IB-Stim therapy. The CPT code reflects the latest medical care available and facilitates consistent reporting and reimbursement for providers. This milestone is seen as a significant breakthrough in the commercialization of NeurAxis's neuromodulation therapies for chronic conditions in children and adults.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet